BLTE – Belite Bio Inc ADR
BLTE — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
2.54
Margin Of Safety %
Put/Call OI Ratio
EPS Next Q Diff
EPS Last/This Y
EPS This/Next Y
2.88
Price
152.93
Target Price
211.5
Analyst Recom
1
Performance Q
-1.89
Upside
-152.9%
Beta
-1.15
Ticker: BLTE
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-03-09 | BLTE | 179.35 | N/A | N/A | 0 |
| 2026-03-10 | BLTE | 174.33 | N/A | N/A | 0 |
| 2026-03-11 | BLTE | 173.65 | N/A | N/A | 0 |
| 2026-03-12 | BLTE | 169.14 | N/A | N/A | 0 |
| 2026-03-13 | BLTE | 169.55 | N/A | N/A | 0 |
| 2026-03-17 | BLTE | 161.93 | N/A | N/A | 0 |
| 2026-03-18 | BLTE | 162.01 | N/A | N/A | 0 |
| 2026-03-19 | BLTE | 158.92 | N/A | N/A | 0 |
| 2026-03-20 | BLTE | 155 | N/A | N/A | 0 |
| 2026-03-23 | BLTE | 151.02 | N/A | N/A | 0 |
| 2026-03-24 | BLTE | 150.6 | N/A | N/A | 0 |
| 2026-03-25 | BLTE | 154.98 | N/A | N/A | 0 |
| 2026-03-26 | BLTE | 148.81 | N/A | N/A | 0 |
| 2026-03-27 | BLTE | 152.47 | N/A | N/A | 0 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-03-09 | BLTE | 179.61 | -43.2 | - | -2.09 |
| 2026-03-10 | BLTE | 174.26 | -43.2 | - | -2.09 |
| 2026-03-11 | BLTE | 173.69 | -43.2 | - | -2.09 |
| 2026-03-12 | BLTE | 169.12 | -43.2 | - | -2.09 |
| 2026-03-13 | BLTE | 164.13 | -43.2 | - | -2.09 |
| 2026-03-17 | BLTE | 162.00 | -43.2 | - | -2.09 |
| 2026-03-18 | BLTE | 161.73 | -43.2 | - | -2.09 |
| 2026-03-19 | BLTE | 159.22 | -43.2 | - | -2.09 |
| 2026-03-20 | BLTE | 154.94 | -43.2 | - | -2.09 |
| 2026-03-23 | BLTE | 150.48 | -43.2 | - | -2.09 |
| 2026-03-24 | BLTE | 150.68 | -43.2 | - | -2.09 |
| 2026-03-25 | BLTE | 155.04 | -43.2 | - | -2.09 |
| 2026-03-26 | BLTE | 148.83 | -43.2 | - | -2.09 |
| 2026-03-27 | BLTE | 152.93 | -43.2 | - | -2.09 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-03-09 | BLTE | 0.00 | 5.57 | 1.75 |
| 2026-03-10 | BLTE | 0.00 | 5.57 | 1.75 |
| 2026-03-11 | BLTE | 0.00 | 5.57 | 2.03 |
| 2026-03-12 | BLTE | 0.00 | 5.57 | 2.03 |
| 2026-03-13 | BLTE | 0.00 | 5.57 | 2.03 |
| 2026-03-17 | BLTE | 0.00 | 5.57 | 2.03 |
| 2026-03-18 | BLTE | 0.00 | 5.57 | 2.03 |
| 2026-03-19 | BLTE | 0.00 | 5.57 | 2.03 |
| 2026-03-20 | BLTE | 0.00 | 5.57 | 2.03 |
| 2026-03-23 | BLTE | 0.00 | 5.55 | 2.03 |
| 2026-03-24 | BLTE | 0.00 | 5.55 | 2.03 |
| 2026-03-25 | BLTE | 0.00 | 5.55 | 2.54 |
| 2026-03-26 | BLTE | 0.00 | 5.55 | 2.54 |
| 2026-03-27 | BLTE | 0.00 | 5.55 | 2.54 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
-0.64
Avg. EPS Est. Next Quarter
-0.67
Insider Transactions
Institutional Transactions
5.55
Beta
-1.15
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
11
Growth Score
23
Sentiment Score
56
Actual DrawDown %
23.5
Max Drawdown 5-Year %
Target Price
211.5
P/E
Forward P/E
117.43
PEG
P/S
P/B
7.76
P/Free Cash Flow
EPS
-2.3
Average EPS Est. Cur. Y
-2.09
EPS Next Y. (Est.)
0.79
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
0.52
Return on Equity vs Sector %
-50.1
Return on Equity vs Industry %
-33.8
EPS 1 7Days Diff
-0.9
EPS 1 30Days Diff
-0.85
EBIT Estimation
◆
BLTE
Healthcare
$152.07
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
37.2
Range 1M
12.4%
Sup Dist
3.5%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
7.3%
EPS NY
160.4%
52W%
68.1%
Long-Term Value
Quality companies, undervalued
WEAK
🔴 SELL
-47.3% upside
Upside
-47.3%
Quality
11
Belite Bio, IncSector: Healthcare
Industry: Biotechnology
Employees:
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an anti-retinol-binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.
BLTE
Latest News
—
Caricamento notizie per BLTE…
stock quote shares BLTE – Belite Bio Inc ADR Stock Price stock today
news today BLTE – Belite Bio Inc ADR stock forecast ,stock prediction 2023 2024 2025
marketwatch BLTE – Belite Bio Inc ADR yahoo finance google finance
stock history BLTE – Belite Bio Inc ADR invest stock market
stock prices BLTE premarket after hours
ticker BLTE fair value insiders trading